65-- Rifampin 600 mg

Request For Information (RFI)/Sources Sought The Government is conducting a Request for Information (RFI) for the product Rifampin 600 mg/vial for injection. Rifampin is a semisynthetic antibiotic derivative of rifamycin. Rifampin is a red-brown crystalline powder, which is very slightly soluble in water at a neutral level, freely soluble in chloroform and soluble in ethyl acetate. Rifampin should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Rifampin for injection contains rifampin 600 mg sodium formaldehyde. It is for intravenous fusion only. This product will have multiple shipping locations throughout the U.S. The information obtained from this RFI will be utilized as market research for consideration in development of the acquisition plan for this requirement, which will eventually result in a Government contractual document. Interested parties are invited to submit a capability statement along with their company profile no later than March 21, 2012. The parties will receive an electronic confirmation acknowledging receipt of response. Please submit your response to Willo Lockett, Contract Specialist at [email protected]. Contact number is 770-488-2525.